Holmes Joseph R. sold $246K of TMO

Holmes Joseph R. (VP & Chief Accounting Officer) sold 420 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $584.81 ($0.25M total) on 2026-08-07.

Original reporting
SEC EDGAR · Holmes Joseph R.
Published Aug 10, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (420 shares, $584.81/share, $245,620.20 total) by a named officer, which may marginally affect sentiment but does not introduce new company fundamentals.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no operational, financial, or regulatory catalyst in the text.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no context on prior grants, option exercises, or total insider activity, limiting inference.

Relevance 4/10Novelty 4/10Timing: Filed 2026-08-10 after-hours; reflects sale executed 2026-08-07.

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, filed on 2026-08-10.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher insider Form 4 shows VP and Chief Accounting Officer Holmes sold 420 shares at $584.81 on 2026-08-07.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited and short-lived.

Evidence & confidence

The filing is a primary-source Form 4 disclosure, but it is a single, modest-sized sale with no stated 10b5-1 plan and no accompanying company-specific news.

Market effects

No clear sector read-through; this is company-specific insider activity without broader regulatory or operational signals.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification or tax/compensation liquidity rather than a bearish view, especially given the lack of any accompanying negative company event.

Key entities

  • Thermo Fisher Scientific Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Holmes Joseph R.

    VP and Chief Accounting Officer who sold 420 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TMOMed

Thermo Fisher Scientific Replenishes Buyback Capacity to $5 Billion

Thermo Fisher Scientific (TMO) authorized up to $5B in new stock repurchases, replacing a prior authorization with $1B remaining. The company spent $4B on buybacks in 2026's first nine months, with no purchases in Q3. Operating cash flow increased to $5.867B for the period, with $4.618B in free cash flow. The new authorization complements acquisitions, dividends, and debt obligations.